Clinical Practice in Prevention of Neonatal HSV Infection: A Survey of Obstetrical Care Providers in Alberta

Kenny, Kathryn; Leung, Wynne I.; Stephanson, Kirk; Ross, Sue

doi:10.1016/s1701-2163(15)31017-3

Cited by 3 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As such, new data sources and better data collection efforts are needed to collect these standardised non-fatal data from diverse healthcare settings. One major need is an understanding of how closely clinicians follow national guidelines on HSV care and treatment, such as the studies by Kenny et al 26 and Heggarty et al 28 from Canada and France, respectively. For example, while there are structured guidelines for the workup of neonatal herpes and its related management, our review did not identify any studies that described the compliance to these guidelines.…”

Section: Discussionmentioning

confidence: 99%

“…Studies within HICs that have national obstetrics guidelines recommending caesarean delivery when HSV lesions are present at delivery have shown that most clinicians follow this guidance. [24][25][26][27] For example, in a Canadian study, caesarean section was offered 'most of the time' to women with HSV lesions at delivery by 92% of obstetricians and 82% of family physicians. 26 In addition, in these settings women with genital herpes are often offered antiviral suppressive therapy in the third trimester.…”

Section: Methodological Heterogeneitymentioning

confidence: 99%

“…[24][25][26][27] For example, in a Canadian study, caesarean section was offered 'most of the time' to women with HSV lesions at delivery by 92% of obstetricians and 82% of family physicians. 26 In addition, in these settings women with genital herpes are often offered antiviral suppressive therapy in the third trimester. 24 26 Both valacyclovir and acyclovir have been used, with difference in preference by country.…”

Section: Methodological Heterogeneitymentioning

confidence: 99%

See 2 more Smart Citations

Healthcare resource utilisation pattern and costs associated with herpes simplex virus diagnosis and management: a systematic review

2022

View full text Add to dashboard Cite

ObjectivesLittle is known about the economic burden of herpes simplex virus (HSV) across countries. This article aims to summarise existing evidence on estimates of costs and healthcare resource utilisation associated with genital and neonatal HSV infection.DesignSystematic literature review.Data sourcesSeven databases were searched from inception to 31 August 2020. A focused search was performed to supplement the results.Eligibility criteriaStudies which reported either healthcare resource utilisation or costs associated with HSV-related healthcare, including screening, diagnosis and treatment of genital HSV infection and neonatal herpes prevention and treatment.Data extraction and synthesisTwo independent reviewers extracted data and assessed the risk of bias using the Larg and Moss’s checklist. All data were summarised narratively.ResultsOut of 11 443 articles, 38 were included. Most studies (35/38, 94.6%) were conducted in high-income countries, primarily the United States, and were more often related to the prevention or management of neonatal herpes (n=21) than HSV genital ulcer disease (n=17). Most analyses were conducted before 2010. There was substantial heterogeneity in the reporting of HSV-related healthcare resource utilisation, with 74%–93% individuals who sought care for HSV, 11.6%–68.4% individuals who received care, while neonates with herpes required a median of 6–34 hospitalisation days. The costs reported were similarly heterogeneous, with wide variation in methodology, assumptions and outcome measures between studies. Cost for screening ranged from US$7–100, treatment ranged from US$0.53–35 for an episodic therapy, US$240–2580 yearly for suppressive therapy, while hospitalisation for neonatal care ranged from US$5321–32 683.ConclusionsA paucity of evidence exists on healthcare resource utilisation and costs associated with HSV infection, especially among low-income and middle-income countries. Future research is needed on costs and healthcare utilisation patterns to improve overall understanding of the global economic burden of HSV.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodological Heterogeneitymentioning

confidence: 99%

Section: Methodological Heterogeneitymentioning

confidence: 99%

See 1 more Smart Citation

Healthcare resource utilisation pattern and costs associated with herpes simplex virus diagnosis and management: a systematic review

2022

View full text Add to dashboard Cite

show abstract

“…The current existant treatment of HSV infection relies mainly on the use of acyclovir (ACV) and related synthetic nucleoside analogs. Unfortunately, the rigorous utilization of these drugs has led to the establishment of undesirable effects as well as drug-resistant strains [8,9]. Although imperative efforts were taken to develop a vaccination, no vaccines have been validated or marketed for effective prevention of the infection to date.…”

Section: Introductionmentioning

confidence: 99%

Natural Products-Derived Chemicals: Breaking Barriers to Novel Anti-HSV Drug Development

Treml

Gazdová

Šmejkal

et al. 2020

Viruses

View full text Add to dashboard Cite

Recently, the problem of viral infection, particularly the infection with herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), has dramatically increased and caused a significant challenge to public health due to the rising problem of drug resistance. The antiherpetic drug resistance crisis has been attributed to the overuse of these medications, as well as the lack of new drug development by the pharmaceutical industry due to reduced economic inducements and challenging regulatory requirements. Therefore, the development of novel antiviral drugs against HSV infections would be a step forward in improving global combat against these infections. The incorporation of biologically active natural products into anti-HSV drug development at the clinical level has gained limited attention to date. Thus, the search for new drugs from natural products that could enter clinical practice with lessened resistance, less undesirable effects, and various mechanisms of action is greatly needed to break the barriers to novel antiherpetic drug development, which, in turn, will pave the road towards the efficient and safe treatment of HSV infections. In this review, we aim to provide an up-to-date overview of the recent advances in natural antiherpetic agents. Additionally, this paper covers a large scale of phenolic compounds, alkaloids, terpenoids, polysaccharides, peptides, and other miscellaneous compounds derived from various sources of natural origin (plants, marine organisms, microbial sources, lichen species, insects, and mushrooms) with promising activities against HSV infections; these are in vitro and in vivo studies. This work also highlights bioactive natural products that could be used as templates for the further development of anti-HSV drugs at both animal and clinical levels, along with the potential mechanisms by which these compounds induce anti-HSV properties. Future insights into the development of these molecules as safe and effective natural anti-HSV drugs are also debated.

show abstract

Nutraceutical Curcumin with Promising Protection against Herpesvirus Infections and Their Associated Inflammation: Mechanisms and Pathways

Šudomová¹,

Hassan

2021

Microorganisms

View full text Add to dashboard Cite

Herpesviruses are DNA viruses that infect humans and animals with the ability to induce latent and lytic infections in their hosts, causing critical health complications. The enrolment of nutraceutical anti-herpesvirus drugs in clinical investigations with promising levels of reduced resistance, free or minimal cellular toxicity, and diverse mechanisms of action might be an effective way to defeat challenges that hurdle the progress of anti-herpesvirus drug development, including the problems with drug resistance and recurrent infections. Therefore, in this review, we aim to hunt down all investigations that feature the curative properties of curcumin, a principal bioactive phenolic compound of the spice turmeric, in regard to various human and animal herpesvirus infections and inflammation connected with these diseases. Curcumin was explored with potent antiherpetic actions against herpes simplex virus type 1 and type 2, human cytomegalovirus, Kaposi’s sarcoma-associated herpesvirus, Epstein–Barr virus, bovine herpesvirus 1, and pseudorabies virus. The mechanisms and pathways by which curcumin inhibits anti-herpesvirus activities by targeting multiple steps in herpesvirus life/infectious cycle are emphasized. Improved strategies to overcome bioavailability challenges that limit its use in clinical practice, along with approaches and new directions to enhance the anti-herpesvirus efficacy of this compound, are also reviewed. According to the reviewed studies, this paper presents curcumin as a promising natural drug for the prevention and treatment of herpesvirus infections and their associated inflammatory diseases.

show abstract

Clinical Practice in Prevention of Neonatal HSV Infection: A Survey of Obstetrical Care Providers in Alberta

Cited by 3 publications

References 24 publications

Healthcare resource utilisation pattern and costs associated with herpes simplex virus diagnosis and management: a systematic review

Healthcare resource utilisation pattern and costs associated with herpes simplex virus diagnosis and management: a systematic review

Natural Products-Derived Chemicals: Breaking Barriers to Novel Anti-HSV Drug Development

Nutraceutical Curcumin with Promising Protection against Herpesvirus Infections and Their Associated Inflammation: Mechanisms and Pathways

Contact Info

Product

Resources

About